IL17A and inflammatory bowel disease: Intervention with AG490 (a highly selective JAK2 inhibitor) in a rat model of inflammatory bowel disease (IBD) significantly decreased the levels of IL-6 and IL-17A and increased the levels of IL-10, suggesting a protective effect on IBD [23].